Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
112 articles about Adicet Bio, Inc.
-
Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical Officer
9/23/2019
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the appointment of Francesco Galimi, M.D., Ph.D., as Senior Vice President and Chief Medical Officer.
-
Adicet Bio Appoints Anil Singhal Chief Executive Officer
4/30/2019
Adicet Bio, Inc. announced that the Board of Directors has appointed Anil Singhal, Ph.D., MBA, President and Chief Executive Officer, effective May 6, 2019.
-
Adicet Bio to Present at the 37th J.P. Morgan Healthcare Conference on January 9
1/7/2019
Adicet Bio, Inc. announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference.
-
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
6/27/2018
Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies.
-
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
4/30/2018
Adicet Bio, Inc. announced that it has appointed Elizabeth "E.J." Read, M.D. as its Chief Technology Officer. Dr. Read brings extensive industry experience in the successful development of cell-based biological therapies.
-
Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits
3/6/2018
Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer.
-
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer
6/28/2017
-
What You Need to Know About Adicet Bio
1/18/2017
-
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014. -
Adicet Bio Appoints Anne Altmeyer As Chief Business Officer
1/5/2017
-
After Bagging $51 Million in Early 2016, Bay Area's Adicet Bio Inks a Five-Year R&D Deal with Regeneron
8/2/2016
-
The Bay Area's Secretive Adicet Bio Raises $51 Million and Buys Israel-based Applied Immune Technologies
1/27/2016